Melanoma Metastatic

Oncology
3
Pipeline Programs
3
Companies
50
Clinical Trials
14 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 1 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

BioInvent International
1 program
1
pembrolizumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT06784648Active Not Recruiting35Est. Dec 2025
M&
Merck & Co.RAHWAY, NJ
1 program
1
pembrolizumabPhase 1/2Monoclonal Antibody5 trials
Active Trials
NCT02083484No Longer Available
NCT07267338Not Yet Recruiting35Est. Jun 2029
NCT07302347Recruiting20Est. Dec 2029
+2 more trials
AO
Alpha-9 OncologyBC - Vancouver
1 program
1
[225Ac]Ac-A9-3408Phase 11 trial
Active Trials
NCT07076550Recruiting50Est. Jan 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab
Merck & Co.pembrolizumab

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 34,428 patients across 50 trials

NCT04489888Merck & Co.pembrolizumab

A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

Start: Oct 2020Est. completion: Jun 2024101 patients
Phase 4Completed
NCT03715205Merck & Co.pembrolizumab

Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

Start: Jan 2019Est. completion: Aug 2024150 patients
Phase 4Completed
NCT07216703Merck & Co.pembrolizumab

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Start: Jan 2026Est. completion: Oct 20311,023 patients
Phase 3Recruiting
NCT07190248Merck & Co.pembrolizumab

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Start: Oct 2025Est. completion: Aug 2032675 patients
Phase 3Recruiting
NCT06966700Merck & Co.pembrolizumab

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Start: Jun 2025Est. completion: Dec 20342,400 patients
Phase 3Recruiting
NCT05815927Merck & Co.pembrolizumab

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

Start: May 2025Est. completion: Mar 2030200 patients
Phase 3Recruiting
NCT06952504Merck & Co.pembrolizumab

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Start: May 2025Est. completion: May 20321,123 patients
Phase 3Recruiting
NCT06726265Merck & Co.pembrolizumab

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Start: Mar 2025Est. completion: Sep 2029756 patients
Phase 3Recruiting
NCT06841354Merck & Co.pembrolizumab

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Start: Mar 2025Est. completion: May 20301,000 patients
Phase 3Recruiting
NCT06556563Merck & Co.pembrolizumab

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Start: Feb 2025Est. completion: Apr 2029741 patients
Phase 3Recruiting
NCT06698042Merck & Co.pembrolizumab

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

Start: Nov 2024Est. completion: Feb 203067 patients
Phase 3Active Not Recruiting
NCT06393374Merck & Co.pembrolizumab

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Start: Jun 2024Est. completion: Dec 20371,530 patients
Phase 3Recruiting
NCT06422143Merck & Co.pembrolizumab

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Start: Jun 2024Est. completion: Feb 2031851 patients
Phase 3Recruiting
NCT06345729Merck & Co.pembrolizumab

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Start: May 2024Est. completion: Feb 2031600 patients
Phase 3Recruiting
NCT06312137Merck & Co.pembrolizumab

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Start: Apr 2024Est. completion: Oct 2034780 patients
Phase 3Recruiting
NCT06170788Merck & Co.pembrolizumab

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Start: Dec 2023Est. completion: May 2030614 patients
Phase 3Recruiting
NCT06212752Merck & Co.pembrolizumab

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Start: Jun 2023Est. completion: May 202839 patients
Phase 3Active Not Recruiting
NCT05633602Merck & Co.pembrolizumab

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Start: Mar 2023Est. completion: Mar 2028838 patients
Phase 3Active Not Recruiting
NCT05722015Merck & Co.pembrolizumab

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

Start: Feb 2023Est. completion: May 2028377 patients
Phase 3Active Not Recruiting
NCT05665595Merck & Co.pembrolizumab

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Start: Jan 2023Est. completion: Sep 20251,594 patients
Phase 3Completed
NCT05600309Merck & Co.pembrolizumab

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Start: Jun 2022Est. completion: Feb 202594 patients
Phase 3Completed
NCT05298423Merck & Co.pembrolizumab

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

Start: May 2022Est. completion: Aug 2026611 patients
Phase 3Active Not Recruiting
NCT05239741Merck & Co.pembrolizumab

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Start: Apr 2022Est. completion: Sep 2028100 patients
Phase 3Recruiting
NCT05224141Merck & Co.pembrolizumab

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

Start: Mar 2022Est. completion: Jun 2027460 patients
Phase 3Active Not Recruiting
NCT05226598Merck & Co.pembrolizumab

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Start: Mar 2022Est. completion: Jan 2026739 patients
Phase 3Completed
NCT05239728Merck & Co.pembrolizumab

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Start: Mar 2022Est. completion: Sep 20291,800 patients
Phase 3Active Not Recruiting
NCT05173987Merck & Co.pembrolizumab

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

Start: Feb 2022Est. completion: May 2027280 patients
Phase 3Active Not Recruiting
NCT05092360Merck & Co.pembrolizumab

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Start: Jan 2022Est. completion: May 2025456 patients
Phase 3Terminated
NCT05116189Merck & Co.pembrolizumab

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

Start: Dec 2021Est. completion: Jul 2027643 patients
Phase 3Active Not Recruiting
NCT05064059Merck & Co.pembrolizumab

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Start: Nov 2021Est. completion: Feb 2025441 patients
Phase 3Completed
NCT04956692Merck & Co.pembrolizumab

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Start: Aug 2021Est. completion: Oct 2026531 patients
Phase 3Active Not Recruiting
NCT04895358Merck & Co.pembrolizumab

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Start: Jun 2021Est. completion: Dec 2027340 patients
Phase 3Active Not Recruiting
NCT04934722Merck & Co.pembrolizumab

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Start: May 2021Est. completion: Sep 2025186 patients
Phase 3Completed
NCT04738487Merck & Co.pembrolizumab

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Start: Apr 2021Est. completion: Jan 20261,264 patients
Phase 3Completed
NCT04634877Merck & Co.pembrolizumab

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Start: Jan 2021Est. completion: Sep 2026990 patients
Phase 3Active Not Recruiting
NCT04624204Merck & Co.pembrolizumab

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Start: Dec 2020Est. completion: Oct 2027672 patients
Phase 3Active Not Recruiting
NCT04907227Merck & Co.pembrolizumab

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Start: Sep 2020Est. completion: Jul 202381 patients
Phase 3Terminated
NCT04428333Merck & Co.pembrolizumab

Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Start: Aug 2020Est. completion: Sep 2023117 patients
Phase 3Terminated
NCT04882241Merck & Co.pembrolizumab

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Start: Jul 2020Est. completion: Apr 2025120 patients
Phase 3Completed
NCT04924062Merck & Co.pembrolizumab

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

Start: Jul 2020Est. completion: Mar 2025158 patients
Phase 3Completed
NCT04380636Merck & Co.pembrolizumab

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Start: Jul 2020Est. completion: Feb 2027870 patients
Phase 3Active Not Recruiting
NCT04241185Merck & Co.pembrolizumab

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Start: May 2020Est. completion: Nov 2031520 patients
Phase 3Active Not Recruiting
NCT04221945Merck & Co.pembrolizumab

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

Start: May 2020Est. completion: Jan 20261,060 patients
Phase 3Completed
NCT04210115Merck & Co.pembrolizumab

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Start: Feb 2020Est. completion: Feb 2027703 patients
Phase 3Active Not Recruiting
NCT04191096Merck & Co.pembrolizumab

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Start: Feb 2020Est. completion: Feb 20261,251 patients
Phase 3Active Not Recruiting
NCT04128696Merck & Co.pembrolizumab

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Start: Nov 2019Est. completion: Jun 2023315 patients
Phase 3Terminated
NCT04003636Merck & Co.pembrolizumab

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

Start: Sep 2019Est. completion: Apr 20251,069 patients
Phase 3Completed
NCT03834493Merck & Co.pembrolizumab

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Start: Jul 2019Est. completion: May 20261,244 patients
Phase 3Active Not Recruiting
NCT03976323Merck & Co.pembrolizumab

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Start: Jun 2019Est. completion: Jan 20261,003 patients
Phase 3Completed
NCT03976362Merck & Co.pembrolizumab

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Start: Jun 2019Est. completion: Jan 2026851 patients
Phase 3Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

14 actively recruiting trials targeting 34,428 patients
Monoclonal Antibody is the dominant modality (100% of programs)
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)